| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
1 Scott Department of Urology, Baylor College of Medicine, Houston, Texas;
2 Laboratory of Cell Regulation and Carcinogenesis and
3 Urology Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland; and
4 Department of Urology, Ewha Women’s University, Seoul, Korea
Purpose: Bone morphogenetic proteins (BMPs) are members of a family of pleiotropic growth factors that play a critical role during renal development as well as maintaining kidney homeostasis. In the present study, we investigated the potential role of BMP receptors (BMPRs) in renal cell carcinoma (RCC) cells.
Experimental Design: Immunohistochemistry was used to investigate the expression of BMPRs in human RCC tissues. As an in vitro model of RCC, three cell lines were used: 112, 117, and 181. Northern blot, immunoblot, and reverse transcription-PCR were used to study the expression of BMPRs in the cell lines. Finally, cells were transfected using LipofectAMINE.
Results: Normal human kidney tissues express the three BMPRs: types RIA, RIB, and RII. In contrast, human RCC cells frequently exhibit a loss of expression of BMP-RII. In tissue culture, BMP-6 inhibits in a dose-dependent manner the proliferation of 112 cells but not of 117 and 181 cells. Assays for BMPRs demonstrated that 117 and 181 cells express low levels of BMP-RII RNA. When these two BMP-6 resistant cell lines were infected with the adenovirus containing the constitutively active form of BMP-RIA or -RIB in combination with a BMP-6-responsive luciferase reporter construct, luciferase activity increased. Finally, when these cell lines were transfected with BMP-RII, BMP-6-sensitivity was restored.
Conclusions: These results demonstrate that human RCC tissues frequently have decreased levels of expression of BMP-RII and that the human RCC cell lines 117 and 181 are resistant to the growth-inhibitory effect of BMP-6 because they have decreased levels of expression of BMP-RII.
This article has been cited by other articles:
|
|
 |
|
  P. B. Yu, D. Y. Deng, H. Beppu, C. C. Hong, C. Lai, S. A. Hoyng, N. Kawai, and K. D. Bloch Bone Morphogenetic Protein (BMP) Type II Receptor Is Required for BMP-mediated Growth Arrest and Differentiation in Pulmonary Artery Smooth Muscle Cells J. Biol. Chem., February 15, 2008; 283(7): 3877 - 3888. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jin, C. Yun, H.-S. Kim, and S.-J. Kim TrkC Binds to the Bone Morphogenetic Protein Type II Receptor to Suppress Bone Morphogenetic Protein Signaling Cancer Res., October 15, 2007; 67(20): 9869 - 9877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Daibata, Y. Nemoto, K. Bandobashi, N. Kotani, M. Kuroda, M. Tsuchiya, H. Okuda, T. Takakuwa, S. Imai, T. Shuin, et al. Promoter Hypermethylation of the Bone Morphogenetic Protein-6 Gene in Malignant Lymphoma Clin. Cancer Res., June 15, 2007; 13(12): 3528 - 3535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Selander, D. A. Brown, G. B. Sequeiros, M. Hunter, R. Desmond, T. Parpala, J. Risteli, S. N. Breit, and A. Jukkola-Vuorinen Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 532 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bursztyn, M.-L. Gross, T. Goltser-Dubner, N. Koleganova, T. Birman, Y. Smith, and I. Ariel Adult Hypertension in Intrauterine Growth-Restricted Offspring of Hyperinsulinemic Rats: Evidence of Subtle Renal Damage Hypertension, October 1, 2006; 48(4): 717 - 723. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
